In today’s recent session, 0.69 million shares of the Viking Therapeutics Inc (NASDAQ:VKTX) have been traded, and its beta is 1.19. Most recently the company’s share price was $64.42, and it changed around $1.0 or 1.58% from the last close, which brings the market valuation of the company to $7.04B. VKTX at last check was trading at a discount to its 52-week high of $99.41, offering almost -54.32% off that amount. The share price’s 52-week low was $8.28, which indicates that the recent value has risen by an impressive 87.15% since then. We note from Viking Therapeutics Inc’s average daily trading volume that its 3-month average coming to 6.45 million.
Viking Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.09. If we narrow it down even further, the data shows that 0 out of 3 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 0 recommended VKTX as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight. Viking Therapeutics Inc is expected to report earnings per share of -$0.28 for the current quarter.
Viking Therapeutics Inc (NASDAQ:VKTX) trade information
Instantly VKTX has been showing a green trend so far today with a performance of 1.58% on intraday trading today. The performance over the last five days has remained in the red territory. The company’s shares are currently up 246.16% year-to-date, but still down -3.78% over the last five days. On the other hand, Viking Therapeutics Inc (NASDAQ:VKTX) is -8.74% down in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $78.8, which translates to bulls needing to increase their stock price by 18.25% from its current value. Analyst projections state that VKTX is forecast to be at a low of $15 and a high of $138.
Viking Therapeutics Inc (VKTX) estimates and forecasts
Viking Therapeutics Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 537.82 percent over the past six months and at a -20.88% annual growth rate that is well below the industry average of 13.30%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will loss -12.00% in revenue this quarter, and will report a decrease of -47.40% in the next quarter.
Consensus estimates provided by 10 financial analysts predict the company will bring in an average of -$ in revenue for the current quarter. 10 analysts expect Viking Therapeutics Inc to make -$ in revenue for the quarter ending Jun 2024.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -18.89%. Viking Therapeutics Inc earnings are expected to increase by -23.49% in 2024, but the outlook is positive 40.00% per year for the next five years.
